Eric DeJesus Featured by ARCS Foundation and ARCS Forward

The ARCS Foundation recently spotlighted Eric DeJesus, PhD, Founder & CEO of Annate Bitherapeutics, for his groundbreaking work in cancer immunotherapy. As an ARCS Scholar Alum, Dr. DeJesus has built on his academic foundation to launch Annate’s therapeutic platform, which leverages innate immunity to fight multiple myeloma and pancreatic cancer.

🎥 Watch the Talk

Dr. DeJesus presented at the June 2025 ARCS Forward event, delivering a talk titled Reducing the Impact of Cancer. In this presentation, he outlines the scientific basis of Annate’s therapies and the company’s vision for addressing unmet needs in oncology.

(Click image to watch the video on YouTube)

📖 Read the Feature

Alongside the event, ARCS published a feature article on Dr. DeJesus, highlighting his journey from ARCS Scholar to biotech entrepreneur:
ARCS Scholar Alum Eric DeJesus Pushes Boundaries in Cancer Treatment

Together, the feature article and the ARCS Forward talk showcase how Annate Bitherapeutics is translating innovative research into a new generation of cancer treatments.